0001209191-18-037472.txt : 20180613
0001209191-18-037472.hdr.sgml : 20180613
20180613163304
ACCESSION NUMBER: 0001209191-18-037472
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180611
FILED AS OF DATE: 20180613
DATE AS OF CHANGE: 20180613
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ANIDO VICENTE JR
CENTRAL INDEX KEY: 0001207633
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36152
FILM NUMBER: 18897061
MAIL ADDRESS:
STREET 1: 1621 BAYSIDE DR
CITY: CORONA DEL MAR
STATE: CA
ZIP: 92625
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AERIE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001337553
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 203109565
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7020 KIT CREEK ROAD
STREET 2: SUITE 270
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: 919-313-9650
MAIL ADDRESS:
STREET 1: 7020 KIT CREEK ROAD
STREET 2: SUITE 270
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-11
0
0001337553
AERIE PHARMACEUTICALS INC
AERI
0001207633
ANIDO VICENTE JR
C/O AERIE PHARMACEUTICALS, INC.
4301 EMPEROR BLVD., SUITE 400
DURHAM
NC
27703
1
1
0
0
Chief Executive Officer
Common Stock
2018-06-11
4
M
0
50000
3.15
A
176320
D
Common Stock
2018-06-11
4
S
0
45004
61.9044
D
131316
D
Common Stock
2018-06-11
4
S
0
4996
62.9203
D
126320
D
Option (Right to Buy)
3.15
2018-06-11
4
M
0
50000
0.00
D
2017-09-12
2023-09-12
Common Stock
50000
846329
D
The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $61.50 to $62.45, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold pursuant to the reporting person's Rule 10b5-1 plan in multiple transactions at prices ranging from $62.50 to $63.05, inclusive.
/s/ Richard J. Rubino, Attorney-in-Fact for Vicente Anido, Jr.
2018-06-13